Low Libido in Women: Hormonal and Non-Hormonal Approaches

Low libido in women means persistently low or absent sexual desire that causes personal distress, and it affects an estimated 26 to 43 percent of women at some point, according to Shifren et al. (2008). Hormonal options such as low dose testosterone therapy and non-hormonal options such as flibanserin, bremelanotide, and mindfulness based therapy each produce measurable but modest benefit, and the right starting point depends on what is actually driving the problem for a given woman.

How Common Is Low Libido in Women?

Low sexual desire is the most frequently reported sexual concern among women worldwide. Epidemiological studies estimate that 26-43% of women experience low desire at some point in their lives, with about 8-12% meeting criteria for clinically significant distress about it [1].

That distinction matters. Many women have lower desire than they once did or lower desire than their partner, but it does not bother them. Low desire becomes a clinical issue only when it causes personal distress. The medical framework should follow the woman's experience, not an arbitrary standard of how much desire is "normal."

Prevalence increases somewhat with age, but low desire is not limited to menopause. Women in their 20s and 30s present with this concern regularly, often driven by different factors than those affecting older women.

HSDD: The Diagnosis and Its Limitations

Hypoactive Sexual Desire Disorder (HSDD) was the diagnostic label used for decades. It was defined as persistently deficient or absent sexual fantasies and desire for sexual activity that causes marked distress or interpersonal difficulty [2].

The DSM-5 merged HSDD with Female Sexual Arousal Disorder into Female Sexual Interest/Arousal Disorder (FSIAD), reflecting the reality that desire and arousal are deeply intertwined in women. In practice, most clinicians still use HSDD because the FDA-approved medications were studied under that framework. The terminology matters less than the clinical reality: a woman is distressed by persistent low desire not explained by another condition, relationship problems alone, or medication effects.

Hormonal Factors Behind Low Desire

Testosterone

Testosterone is not just a "male hormone." Women produce testosterone in the ovaries and adrenal glands, and it plays a significant role in sexual desire, arousal, and orgasmic function. Women's testosterone levels peak in their early 20s and decline gradually, dropping roughly 50% by menopause [3].

After surgical menopause (removal of both ovaries), testosterone levels fall abruptly and dramatically. This often correlates with a sharp drop in desire that estrogen therapy alone does not fully restore. Readers who want more detail on this specific pathway can see our separate piece on surgical menopause.

However, there is no well-established testosterone threshold below which desire predictably disappears. Some women function well sexually with relatively low testosterone. Others are symptomatic at levels that look "normal" on a lab test. This makes clinical management more nuanced than simply checking a number, and it is one reason low testosterone symptoms in women are often missed on a standard panel.

Estrogen

Estrogen's role in desire is indirect but important. During perimenopause and menopause, declining estrogen causes vaginal dryness, thinning of vaginal tissue, and pain with intercourse. When sex hurts, avoidance behavior naturally follows, and the brain starts associating sexual situations with discomfort rather than pleasure [4].

This creates a cycle: low estrogen causes vaginal atrophy, which causes pain, which causes avoidance, which gets labeled as "low desire." In many cases, treating the vaginal atrophy reveals that desire was intact all along. The body was simply protecting itself from a painful experience. A broader rundown of the hormonal timeline is in our perimenopause guide.

Thyroid Dysfunction

Both hypothyroidism and hyperthyroidism affect sexual function. Hypothyroidism is particularly associated with decreased desire, reduced arousal, and difficulty with orgasm. A 2018 study found that 46% of women with hypothyroidism reported sexual dysfunction compared to 20% of euthyroid controls [5]. Thyroid function should be checked in any evaluation of persistent low desire, especially if accompanied by fatigue, weight changes, or mood shifts; see our overview of thyroid symptoms for the fuller symptom picture.

Cortisol and the Stress Response

Chronic stress elevates cortisol, which suppresses the hypothalamic-pituitary-gonadal (HPG) axis. This reduces production of both testosterone and estrogen. But the effect goes beyond hormones. When the nervous system is in a persistent threat-detection state, the brain deprioritizes sexual interest. From an evolutionary standpoint, this makes sense. Your body diverts resources away from reproduction when survival feels uncertain.

Postpartum and Breastfeeding

Pregnancy and the postpartum period bring some of the most pronounced hormonal shifts a woman experiences. Prolactin, elevated during lactation, suppresses estrogen and testosterone production, and many breastfeeding women notice persistently low desire that does not track with how they feel about their relationship or their body. Sleep deprivation, physical recovery from delivery, and the demands of caring for a newborn compound the hormonal effect. For most women desire gradually returns as breastfeeding frequency decreases and hormone levels normalize, though the timeline varies widely and a prolonged absence of desire still deserves evaluation rather than being written off as expected.

Non-Hormonal Factors

Medications

SSRIs and SNRIs are among the most common causes of medication-induced low desire. Between 40-65% of people on these medications experience sexual side effects, including reduced desire, delayed orgasm, or anorgasmia [6]. Other medications that can suppress libido include hormonal contraceptives (some formulations more than others), antihypertensives, antihistamines, and opioids.

If low desire started around the time a new medication began, that connection needs to be explored with your prescriber. Switching to bupropion, mirtazapine, or other antidepressants with lower sexual side effect profiles can make a significant difference.

Relationship Dynamics

Desire does not exist in a vacuum. Research consistently shows that relationship satisfaction is one of the strongest predictors of sexual desire in women. Unresolved conflict, feeling undervalued, unequal division of household labor, lack of emotional intimacy, and partner sexual dysfunction all suppress desire [7]. Erectile difficulty on a partner's side is a common and underdiscussed contributor; our comparison of ED treatment options and the discussion of ED and heart health cover that side of the equation.

This is not about pathologizing the woman. If desire is low because a relationship is not functioning well, the treatment is the relationship, not a medication. Couples therapy or sex therapy is the appropriate intervention.

Body Image and Self-Consciousness

Cognitive distraction during sexual activity, often called "spectatoring," is a well-documented inhibitor of arousal and desire. Women preoccupied with how their body looks during sex have significantly lower satisfaction and desire. This affects women across all body types.

History of Trauma

Sexual trauma and negative early sexual experiences can profoundly affect desire, often operating outside conscious awareness. Trauma-informed therapy with a qualified provider is essential in these cases.

Testosterone Therapy for Women

Testosterone supplementation for women with low desire has the strongest pharmacological evidence of any treatment for this condition. A 2019 systematic review and meta-analysis of 36 randomized controlled trials found that transdermal testosterone consistently increased satisfying sexual events, desire, and arousal in postmenopausal women [3].

The effect sizes were moderate but clinically meaningful. Women on testosterone reported approximately one additional satisfying sexual event per month compared to placebo, along with improvements in desire, arousal, and orgasm scores.

Dosing and Delivery

The evidence supports testosterone doses that raise levels into the premenopausal physiological range (roughly 1-3.5 nmol/L total testosterone). This typically means transdermal application: a testosterone cream or gel applied daily at roughly one-tenth the male dose [8]. These preparations are usually compounded; our overview of bioidentical hormone therapy explains how compounding pharmacies formulate them.

Oral testosterone and injections are not recommended for women due to unpredictable blood levels and greater risk of androgenic side effects (acne, hair growth, voice deepening).

The Regulatory Situation

Here is the frustrating reality: no testosterone product is FDA-approved for women in the United States. The Australian product Androfeme (1% testosterone cream) is approved specifically for female HSDD, but it is not available in the US. American women who receive testosterone therapy get it off-label, typically from compounding pharmacies.

Major medical societies, including the International Society for the Study of Women's Sexual Health (ISSWSH) and the Endocrine Society, have published position statements supporting testosterone use in postmenopausal women with HSDD, with appropriate monitoring [8]. The gap between evidence and regulatory status is a policy issue, not a science one. Women evaluating this option can review the hormone replacement therapy guide for how testosterone fits alongside estrogen and progesterone, and can use the hormone therapy clinic directory to see which clinics in their area offer hormone evaluation and monitoring; listing order there reflects the directory's own display logic, not paid placement, and a Verified label means a clinic completed credential checks, not that it paid for visibility.

Monitoring

Women on testosterone therapy should have blood levels checked at 3-6 weeks and then every 6 months. Providers should also monitor lipid panels and watch for androgenic side effects. At physiological female doses, virilization is rare but possible if dosing is not carefully managed.

FDA-Approved Medications

Flibanserin (Addyi)

Flibanserin is a serotonin receptor agonist/antagonist taken daily at bedtime. It works on central neurotransmitter pathways rather than hormones, reducing serotonin (which inhibits desire) while increasing dopamine and norepinephrine (which promote it) [9].

Efficacy: Clinical trials showed an average increase of 0.5-1 additional satisfying sexual events per month compared to placebo. Desire scores improved modestly. About one-third of women experience a clinically meaningful response.

The downsides are real: flibanserin requires daily dosing (unlike an as-needed medication), takes 4-8 weeks to reach full effect, cannot be combined with alcohol (risk of severe hypotension and syncope), and causes dizziness, drowsiness, and nausea in a significant minority. Many women try it and discontinue within 6 months.

Bremelanotide (Vyleesi)

Bremelanotide is a melanocortin receptor agonist given as a subcutaneous injection 45 minutes before anticipated sexual activity. It works through a different mechanism than flibanserin, activating melanocortin pathways involved in sexual arousal [9].

Efficacy is similar to flibanserin: modest but statistically significant improvements in desire and reductions in distress. The main advantages are that it is used on-demand rather than daily and has no alcohol interaction.

The main side effect is nausea, which affects about 40% of women with the first dose and tends to decrease with subsequent use. It can also cause transient increases in blood pressure, so it is not recommended for women with uncontrolled hypertension or cardiovascular disease.

Neither of these medications is a "female Viagra." They produce modest average benefits, and the women who respond well tend to have clearly identifiable HSDD without significant relationship, mood, or hormonal confounders. Setting realistic expectations is important.

Treating Vaginal Atrophy and Pain

When vaginal dryness and pain are contributing to avoidance and declining desire, treating the genital tissue directly can be remarkably effective. Clinicians now use the term genitourinary syndrome of menopause to describe this pattern, and it overlaps substantially with what used to be called atrophic vaginitis [4].

• Local estrogen: Vaginal estrogen creams, tablets, or rings deliver low-dose estrogen directly to vaginal tissue. Systemic absorption is minimal. These treatments restore vaginal elasticity, lubrication, and pH, and are safe even in women for whom systemic estrogen therapy is contraindicated [4].
• Intravaginal DHEA (prasterone): FDA-approved for painful intercourse due to menopause. DHEA is converted locally to both estrogen and testosterone in vaginal tissue. Some women prefer it because it provides both hormonal effects without systemic estrogen.
• Ospemifene: An oral SERM (selective estrogen receptor modulator) approved for painful intercourse. It provides estrogenic effects on vaginal tissue without being an estrogen. An option for women who prefer an oral treatment.

For many women, resolving pain through these treatments restores the desire that was suppressed by a conditioned avoidance response. This is often the single most impactful intervention in perimenopausal and postmenopausal women presenting with "low desire." A clinician working through broader menopause treatment options will typically address this alongside any systemic hormone decisions.

Psychological Approaches

Mindfulness-Based Therapy

Mindfulness-based cognitive therapy adapted for sexual concerns has surprisingly strong evidence. Lori Brotto's research group has published multiple studies showing that mindfulness training improves sexual desire, arousal, and satisfaction in women with HSDD. A 2022 randomized trial found that a group-based mindfulness intervention was as effective as a psychoeducation/cognitive behavioral intervention [10].

The mechanism is straightforward: mindfulness reduces the cognitive distraction and self-judgment that suppress arousal. By training attention to stay with physical sensations rather than drifting to performance anxiety, body image concerns, or to-do lists, women experience more of the arousal signals that drive desire.

Sensate Focus

Originally developed by Masters and Johnson, sensate focus is a structured series of touching exercises designed to reduce performance pressure and rebuild physical intimacy. Couples progress through stages from non-genital touching to genital touching to intercourse, with clear rules that take "performance" off the table.

Sensate focus works well when anxiety, pressure, or disconnection is driving the desire problem. It is often part of sex therapy with a certified sex therapist (look for AASECT certification).

Cognitive Behavioral Therapy (CBT)

CBT for low desire addresses the thought patterns that interfere with sexual motivation: catastrophic thinking about sexual "failure," rigid beliefs about how desire should work, and avoidance patterns. It is particularly useful for women whose desire issue has become entangled with anxiety or depression.

Comparing the Main Treatment Options

Each treatment above works through a different mechanism, which is why combining approaches often helps more than relying on any single option. The table below summarizes the mechanism, delivery, and regulatory status of the options already discussed, based on the trial data and position statements cited throughout this piece.

The Biopsychosocial Model: Putting It Together

Female sexual desire operates on the intersection of biology, psychology, and social context. This is not a platitude. It is a clinical reality that determines treatment success. A woman with low testosterone, relationship stress, and SSRI-induced anorgasmia will not respond to any single intervention.

Effective evaluation means assessing all three domains:

• Biological: Hormone levels (testosterone, estrogen, thyroid, prolactin), medication review, pain assessment, chronic illness screening
• Psychological: Mood disorders, body image, trauma history, cognitive patterns around sex, stress levels
• Social/Relational: Relationship satisfaction, partner health and function, life stage demands, cultural attitudes toward sexuality

Treatment should address what is actually driving the problem, not default to a medication because it is the simplest intervention. Sometimes the right answer is testosterone. Sometimes it is changing an SSRI. Sometimes it is couples therapy. Often it is a combination.

Lifestyle and Self-Care Strategies

Lifestyle factors do not replace medical evaluation when desire has dropped sharply or persists for months, but they shape the baseline a woman is working from and are worth addressing alongside any hormonal or psychological treatment.

1. Protect sleep. Poor sleep lowers testosterone and raises cortisol, both of which work against desire. Treating sleep apnea or chronic insomnia often improves desire as a secondary effect.
2. Moderate alcohol. Alcohol is sometimes used to lower inhibition, but regular heavier use blunts arousal physiology and can worsen depression, which independently suppresses desire.
3. Stay physically active. Regular aerobic activity supports healthy circulation, mood, and body image, all of which feed into desire indirectly.
4. Use lubricants and vaginal moisturizers. For women not ready for or not candidates for hormonal treatment, a good non-hormonal lubricant reduces the friction and discomfort that drive avoidance.
5. Consider pelvic floor physical therapy. A pelvic floor physical therapist can address muscle tension and pain patterns that make intercourse uncomfortable, independent of hormone status.
6. Protect time and context for intimacy. Desire in women, especially in long relationships, is often responsive rather than spontaneous. Deliberately creating low-pressure time together can matter as much as any single treatment.

When to Seek Evaluation

Consider a clinical evaluation if:

• Low desire has persisted for 6 months or longer and causes personal distress
• Desire change coincided with a new medication, surgery, or medical diagnosis
• Pain during sex is contributing to avoidance
• You suspect a hormonal shift (perimenopause, postpartum, thyroid symptoms)
• Low desire is accompanied by fatigue, mood changes, or other systemic symptoms

The right starting point depends on the likely driver. A gynecologist or endocrinologist for hormonal evaluation. A sex therapist or psychologist for psychological factors. Ideally, a sexual medicine specialist who can evaluate all domains. These specialists are becoming more accessible through academic medical centers and through the ISSWSH provider directory. Our hormone therapy guide and guide to finding a menopause specialist walk through how to prepare for that first appointment.

Frequently asked questions

What counts as low libido in women?

Low libido means a persistent drop in sexual thoughts, fantasies, or interest in sexual activity that causes personal distress, not simply having less desire than a partner or than at an earlier life stage. Clinicians distinguish a normal variation in desire from Hypoactive Sexual Desire Disorder by whether the change is distressing and whether it lasts six months or longer according to ISSWSH diagnostic criteria (Clayton et al., 2018).

Can low libido in women be treated?

Yes, though no single treatment works for everyone. Options include low dose testosterone therapy, the FDA-approved medications flibanserin and bremelanotide, local vaginal estrogen or DHEA for pain-related avoidance, and psychological approaches such as mindfulness-based therapy and sensate focus. Most women respond best when treatment targets the specific hormonal, medical, psychological, or relational factor driving their symptoms rather than a single generic approach.

Does testosterone therapy help with low sex drive in women?

Supported by a 2019 meta-analysis of 36 randomized controlled trials, transdermal testosterone increased satisfying sexual events, desire, and arousal in postmenopausal women compared with placebo (Islam et al., 2019). No testosterone product is FDA-approved for women in the United States, so treatment is off-label, typically through a compounding pharmacy, and requires monitoring of blood levels and lipids.

Can antidepressants cause low libido in women?

Yes. SSRIs and SNRIs cause sexual side effects, including reduced desire, delayed orgasm, or anorgasmia, in an estimated 40 to 65 percent of people who take them (Serretti and Chiesa, 2009). If low desire began after starting an antidepressant, discussing a dose change or a switch to an agent such as bupropion or mirtazapine with the prescriber is a reasonable next step rather than assuming the effect is permanent.

Is low libido normal during perimenopause and menopause?

A drop in desire is common during perimenopause and menopause, driven by declining estrogen and testosterone and by vaginal dryness that makes intercourse uncomfortable. It is common enough to be considered part of the menopause transition for many women, but common does not mean it has to be left untreated, since local estrogen, DHEA, ospemifene, and systemic hormone therapy all have evidence for improving it.

What is the difference between HSDD and normal low desire?

Hypoactive Sexual Desire Disorder is diagnosed only when low desire is persistent, not better explained by a relationship problem, another medical condition, or a medication, and causes clinically significant distress to the woman herself. A woman with lower desire than her partner but no personal distress about it does not meet criteria for HSDD, even though the desire discrepancy is real.

Related Reading

• Sexual Wellness: The Evidence-Based Guide (Pillar)
• Perimenopause Symptoms: What to Expect and When
• ED Treatments Compared: PDE5 Inhibitors vs P-Shot vs Shockwave
• TRT Side Effects: What to Expect and How to Manage Them
• ED and Heart Health: What the Vascular Connection Means

Sources

1. Shifren JL, Monz BU, Russo PA, et al. Sexual problems and distress in United States women: prevalence and correlates. Obstet Gynecol. 2008;112(5):970-978. doi:10.1097/AOG.0b013e3181898cdb ↩
2. Clayton AH, Goldstein I, Kim NN, et al. The International Society for the Study of Women's Sexual Health process of care for management of hypoactive sexual desire disorder in women. Mayo Clin Proc. 2018;93(4):467-487. doi:10.1016/j.mayocp.2017.11.002 ↩
3. Islam RM, Bell RJ, Green S, et al. Safety and efficacy of testosterone for women: a systematic review and meta-analysis of randomised controlled trial data. Lancet Diabetes Endocrinol. 2019;7(10):754-766. doi:10.1016/S2213-8587(19)30189-5 ↩
4. Portman DJ, Gass ML; Vulvovaginal Atrophy Terminology Consensus Conference Panel. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women's Sexual Health and the North American Menopause Society. Menopause. 2014;21(10):1063-1068. doi:10.1097/GME.0000000000000329 ↩
5. Atis G, Dalkilinc A, Altuntas Y, et al. Sexual dysfunction in women with clinical hypothyroidism and subclinical hypothyroidism. J Sex Med. 2010;7(7):2583-2590. doi:10.1111/j.1743-6109.2010.01815.x ↩
6. Serretti A, Chiesa A. Treatment-emergent sexual dysfunction related to antidepressants: a meta-analysis. J Clin Psychopharmacol. 2009;29(3):259-266. doi:10.1097/JCP.0b013e3181a5233f ↩
7. Mark KP, Murray SH. Gender differences in desire discrepancy as a predictor of sexual and relationship satisfaction in a college sample of heterosexual romantic relationships. J Sex Marital Ther. 2012;38(2):198-215. doi:10.1080/0092623X.2011.606877 ↩
8. Davis SR, Baber R, Panay N, et al. Global consensus position statement on the use of testosterone therapy for women. J Clin Endocrinol Metab. 2019;104(10):4660-4666. doi:10.1210/jc.2019-01603 ↩
9. Jaspers L, Feys F, Bramer WM, et al. Efficacy and safety of flibanserin for the treatment of hypoactive sexual desire disorder in women: a systematic review and meta-analysis. JAMA Intern Med. 2016;176(4):453-462. doi:10.1001/jamainternmed.2015.8565 ↩
10. Brotto LA, Bergeron S, Engel B, et al. A comparison of mindfulness-based cognitive therapy vs cognitive behavioral sex therapy for the treatment of provoked vestibulodynia in a hospital clinic setting. J Sex Med. 2022;19(4):621-634. doi:10.1016/j.jsxm.2022.01.527 ↩